Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Newest findings from Eisai’s robust Alzheimer’s illness (ADVERTISEMENT) pipeline consist of arise from lecanemab longterm information, an immunoassay for determining amyloid-B protofibrils in cerebrospinal fluid, and asubcutaneousl kind of lecanemab for ongoing treatment of advertisement
Advertisement is a progressive, unrelenting illness brought on by a constant underlying neurotoxic procedure that starts before and continues after plaque deposition
TOKYO, July 22, 2025 – (JCN Newswire) –Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) revealed today that the business will provide the most recent findings from its robust Alzheimer’s illness (ADVERTISEMENT) pipeline and research study, including our dual-acting, anti-amyloid beta (AB) protofibril antibody for the treatment of advertisement, lecanemab (generic name, U.S. brand: LEQEMBI ®), and anti-MTBR (microtubule binding area) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference (AAIC), being kept in Toronto and essentially from July 27-31. Eisai will provide 21 oral discussions, 24 posters, 3 (3) seminar and 2 (2 )lecanemab item theaters.
Secret Oral Lecanemab Presentations
– Four-year Data: On Wednesday July 30 (8:00– 8:45 AM EDT), as part of the “Developing Topics Session: Innovative Therapeutic Approaches”, preliminary four-year findings will exist on lecanemab from the Phase III Clarity Advertisement Open-Label Extension in Early Alzheimer’s Disease trial.
– Subcutaneous Maintenance Dosing: A Featured Research Session on Wednesday, July 30 (9:00– 10:30 AM EDT) will consist of information on the capacity of a brand-new and hassle-free choice for continuous lecanemab treatment, the subcutaneous formula for upkeep dosing.
– Real World Case Studies: A Developing Topics Session on Sunday, July 27 (9:00– 10:30 AM EDT) will consist of information on real-world case research studies and client path knowings from varied U.S. medical settings 2 years post-approval of lecanemab.
Secret Lecanemab Poster Presentation
– A Poster Presentation on Monday, July 28 (seeing readily available from 7:30 AM– 4:15 PM EDT) will share findings on cerebrospinal fluid (CSF) samples gathered from the Clarity advertisement trial and evaluated utilizing the unique, delicate immunoassay established to determine amyloid-B protofibrils in CSF.
Secret Oral E2814 Presentation
– A Featured Research Session on Wednesday, July 30 (4:15 PM– 5:45 PM EDT) will consist of findings from “Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer’s Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial.”
“The information provided at AAIC 2025 will highlight long-lasting findings from lecanemab’s open-label extension trial, real-world lecanemab case research studies in addition to outcomes on a subcutaneous solution and dosing routines that might use clients more versatility to continue treatment to combat Alzhierm’s illness,” stated LynnD. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “Eisai will likewise share initial arise from the DIAN-TU-001 NexGen Trial, checking out etalanetug with background lecanemab treatment to slow or avoid the development of Alzhierm’s illness. As we acquire more experience utilizing dual-acting lecanemab in various medical settings and continue to check out brand-new opportunities to enhance the medical diagnosis and treatment of Alzhierm’s illness, we are confident about the future. We stay dedicated to clients and their liked ones who are affected by this progressive, ruthless illness, brought on by a constant underlying neurotoxic procedure that starts before and continues after plaque is gotten rid of from the brain.”
For more information, please see: https://www.eisai.com/news/2025/pdf/enews202548pdf.pdf
Copyright © 2025 JCN Newswire. All rights booked. A department of Japan Corporate News Network.
